CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Taysha Gene Therapies Q3 net loss widens on higher R&D costs

By Reuters News


Overview

  • US gene therapy developer's Q3 net loss widened yr/yr due to higher R&D and admin expenses

  • Company reported no revenue for Q3 2026

  • TSHA-102 trials showed no severe treatment-related adverse events as of November 2026 data cutoff


Outlook

  • Company expects topline data from REVEAL pivotal trial 6-month interim analysis in 1H 2027

  • FDA feedback on BLA submission pathway for TSHA-102 expected in 1H 2027

  • Company expects to nominate a new gene therapy candidate and begin preclinical work in 1H 2027


Result Drivers

  • HIGHER CLINICAL TRIAL COSTS - Co said increased R&D expenses were mainly due to higher clinical expenses from REVEAL, pivotal and ASPIRE trials for TSHA-102

  • INCREASED ADMINISTRATIVE COSTS - Co attributed higher G&A expenses to increased compensation and commercial launch-readiness initiatives

  • MANUFACTURING MILESTONE - Co completed BLA-enabling manufacturing campaign for TSHA-102, meeting product specifications and comparability criteria


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.10

Q3 Net Loss

$39.13 mln

Q3 Operating Expenses

$41.87 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Taysha Gene Therapies, Inc. is $12.00, about 180.4% above its November 11 closing price of $4.28


Reuters Recommended Reads

  • Nov 10 - Tyra Biosciences Q3 net loss widens on higher R&D costs

  • Nov 9 - Structure Therapeutics Q3 loss widens on higher R&D costs

  • Nov 10 - Biotech firm PepGen's Q3 net loss widens as R&D expenses rise


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.